Pfizer scraps daily weight loss pill danuglipron after a liver injury

Pfizer Monday said finishing the development of their experimental Daily weight loss pill After a patient experienced a wound of the liver that was potentially caused by the drug in a process.

The patient has not experienced any symptoms of liver or side effects, a pfizer portfolio said in a statement. They add the enzymes of the patient “to resembling quickly” after they were planted to take the pill, that is a drug oral mad call dauglier. The statement suggests the patient’s liver enzymes were high, that often indicates damage to cells In the organ and is a problem that has been related to some other obesity drugs.

The case occurred in a test that is quickly holding the dose of the pill on a period of time, the portface told. Pfizer’s decision to beat the drug development has come later “a review of information is including all the clinical data for the unrecusted and regulators” according to a release “

“While we are disappointed to discontinue development development, we remain busy and notice a new amonic with an effort”, the chris delly, the chief, he said in the release. Added that company is always developed other weight loss drug.

The advertisement announcement to a practice chain to win a slices of glp-1s of GLP-1 orremagne to flip the appetite and regulate blood sugar. Pfizer is between the racing drugwers to bring a loss of weight more convenient to an area dominated by weekly injections but it is years behind competitors as Lilly eli and it Nine noralymous. I am

Some Wall Street analysts wait for the glp-1 industry worth of $ 150 billion. GLP-1S could increase $ 50 billion, whereas the injections should count for rest, according to some analyst estimate. I am

This is not the first pfizer pace with dauggy, specifically, either. The society discontinued A version twice in December in December 2023 After patients had trouble tolerating the drug in a middle view.

But the pfizer seemed to be confident in the form once daddy danuliglon again in July, when he said start driving studies In the second half of the year to assess several doses of the pill.

Despite his decision to scratch the drug, pfizer monday claimed those studies and confirmed a certain form with the competitive trials “in the terrability.

The company also noticed that the rate of raised felps of liver In people who took Danuliglon are in line with GLP-1 drugs, which is based on a safety database of more than 1,400 catching the pill.

Pfizer has discarded a different rid of a vault after the 2023 pilies that took that drug has had the higher liver levels in a half-exchange exchange proof. Investors have been pessimists on the company potential in glp-1 space since.

However, pfizer has Other experimental Their obesity drug in their pipeline in the first development stages that looked to work in a way in a way in a wise manner. That includes an oral drug that blocks a foul named two processes last year, and a higher daily woman in phase a

The pfizer believes that a drug Girading could be more effective for patients, in order to tolerate the compulsion Mikael, who is up to investors. Added that “there are so many applications for glp-1s”.

The pfizer damulger promotes weight loss from the glp-1, who is also as the weight of the weight of the 2 nordisk injection and diabetes the ozpic work. Eli Lilly’s loss of the weight of Zapbound’s weight and Diabetes Shot Mounjaro Target GLP-1 but also activate another Hormon called GIP.

The only glp-1 oral approved of food administration is on Novo Nordisk is Rybelsus, that deals 2 diabetes and raked in about $ 3.38 billion Sales in 2024.

The Monday Pfizer’s announcement comes as the company regains its foot and If you recover its share price after the quick decline of their coward company. PFERDE has betrow off the loading drug pipeline to carry the long-term growing, but has emphasized that obesity is a key focus.